Precision Medicine Markets Projected to Reach $345.75B by 2035
Precision diagnostics and medicine market is projected to reach USD 345.75 billion by 2035, while US personalized medicine is set to surpass US$ 307 billion by 2033. AI, single-cell analysis, and clinical laboratory markets also show strong growth.
Global precision healthcare markets are forecast to expand rapidly over the coming decade, with the precision diagnostics and medicine market projected to reach USD 345.75 billion by 2035 and the United States personalized medicine market set to surpass US$ 307 billion by 2033. Multiple market reports also project strong growth in AI-driven drug discovery, single-cell analysis, clinical laboratory services, and related data analytics segments.
The global precision diagnostics and medicine market was valued at approximately USD 147.23 billion in 2025, is expected to reach USD 159.66 billion in 2026, and is projected to reach around USD 345.75 billion by 2035, with a compound annual growth rate (CAGR) of about 8.91%. The market is driven by increasing adoption of advanced molecular diagnostics, genomic sequencing, companion diagnostics, pharmacogenomics, liquid biopsy, biomarker testing, AI-driven diagnostics, digital pathology, and multi-omics technologies.
The United States personalized medicine market is projected to grow from US$ 169.56 billion in 2024 to US$ 307.04 billion by 2033, expanding at a CAGR of 6.82% during 2025–2033. Advancements in genomics, AI-driven diagnostics, targeted therapies, and supportive government initiatives are accelerating adoption.
The AI in omics studies market is expanding from $1.23 billion in 2025 to an anticipated $5.55 billion by 2030, at a CAGR of 35%, driven by next-generation sequencing technologies, bioinformatics tools, and increased access to biological big data. The AI in drug discovery market is projected to grow from USD 1.86 billion in 2024 to USD 6.89 billion by 2029, registering a CAGR of 29.9%. Key drivers include the need to reduce drug discovery timelines and costs, improve target identification accuracy, and the growing use of generative AI in molecular design.
The global single cell analysis market is projected to expand from USD 3.81 billion in 2025 to USD 7.56 billion by 2030, at a CAGR of 14.7%. North America led the single-cell analysis market in 2024 with a 43.1% share.
The clinical laboratory services market is forecast to surpass $418.25 billion by 2030, with a CAGR of 6%. North America will be the largest region in 2030, valued at $185 billion, and the USA will be the largest country, valued at $169 billion. The global clinical data analytics solutions market is expected to grow from US$ 5.3 billion in 2024 to US$ 11.8 billion by 2034, at a CAGR of 8.3%.
The de-identified health data market is projected to increase from USD 9.8 billion in 2026 to USD 30.7 billion by 2036, at a 12.1% CAGR. The United States target enrichment probes market is projected to grow at a compound annual rate of 7–9% between 2026 and 2035, driven by precision medicine and companion diagnostic development.
Common growth factors cited across these reports include the increasing prevalence of cancer and chronic diseases, expansion of genomic medicine programs, growing demand for personalized and preventive healthcare, and rising investment in life sciences research. The Personalized Medicine Coalition highlighted that the US FDA approved 16 new personalized treatments for rare diseases in 2023.